Literature DB >> 11502003

High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene.

R C Hillig1, P G Coulie, V Stroobant, W Saenger, A Ziegler, M Hülsmeyer.   

Abstract

The heterotrimeric complex of the human major histocompatibity complex (MHC) molecule HLA-A*0201, beta2-microglobulin and the decameric peptide GVYDGREHTV derived from the melanoma antigen (MAGE-A4 protein has been determined by X-ray crystallography at 1.4 A resolution. MAGE-A4 belongs to a family of genes that are specifically expressed in a variety of tumours. MAGE-A4-derived peptides are presented by MHC molecules at the cell surface to cytotoxic T-lymphocytes. As the HLA-A*0201:MAGE-A4 complex occurs only on tumour cells, it is considered to be an appropriate target for immunotherapy. The structure presented here reveals potential epitopes specific to the complex and indicates which peptide residues could be recognised by T-cell receptors. In addition, as the structure could be refined anisotropically, it was possible to describe the movements of the bound peptide in more detail.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502003     DOI: 10.1006/jmbi.2001.4816

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  16 in total

Review 1.  Rational design of peptide-based tumor vaccines.

Authors:  Wilson S Meng; Lisa H Butterfield
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

2.  Conformational flexibility of the MHC class I alpha1-alpha2 domain in peptide bound and free states: a molecular dynamics simulation study.

Authors:  Martin Zacharias; Sebastian Springer
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

3.  Structure of HLA-A*1101 in complex with a hepatitis B peptide homologue.

Authors:  Thomas Blicher; Jette Sandholm Kastrup; Lars Østergaard Pedersen; Søren Buus; Michael Gajhede
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-04

4.  An altered CD8+ T cell epitope of insulin prevents type 1 diabetes in humanized NOD mice.

Authors:  Mengjun Zhang; Shufeng Wang; Binbin Guo; Gang Meng; Chi Shu; Wenli Mai; Qian Zheng; Xiaoling Chen; Yuzhang Wu; Li Wang
Journal:  Cell Mol Immunol       Date:  2018-06-28       Impact factor: 11.530

5.  Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.

Authors:  Oleg Y Borbulevych; Tiffany K Baxter; Zhiya Yu; Nicholas P Restifo; Brian M Baker
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

6.  Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.

Authors:  Philip C Simister; Ellen C Border; João F Vieira; Nicholas J Pumphrey
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 7.  Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities.

Authors:  Kathryn M Armstrong; Francis K Insaidoo; Brian M Baker
Journal:  J Mol Recognit       Date:  2008 Jul-Aug       Impact factor: 2.137

8.  Sequence of beta(2)-microglobulin from rhesus macaque ( Macaca mulatta) includes an allelic variation in the 3'-untranslated region.

Authors:  Jin Su; Mark A Luscher; Kelly S MacDonald
Journal:  Immunogenetics       Date:  2004-02-12       Impact factor: 2.846

9.  Structure of a classical MHC class I molecule that binds "non-classical" ligands.

Authors:  Chee Seng Hee; Song Gao; Bernhard Loll; Marcia M Miller; Barbara Uchanska-Ziegler; Oliver Daumke; Andreas Ziegler
Journal:  PLoS Biol       Date:  2010-12-07       Impact factor: 8.029

10.  Evolutionary history of the cancer immunity antigen MAGE gene family.

Authors:  Yukako Katsura; Yoko Satta
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.